P&G in talks for Pfizer consumer health business

Apr 03, 2018

While numerous potential buyers, including GlaxoSmithKline and Johnson & Johnson, have already backed out, Procter & Gamble is still in talks with Pfizer on the sale of its consumer business according to a CNBC report. The two organizations are allegedly not close on a price.  

CNBC reporter David Faber says that while Pfizer is hoping to sell for around $20 billion, P&G's hoping to snag the consumer unite for $15 or $16 billion.

Hoping to finalize a decision by the end of the month, Pfizer is still mulling its options, which include a joint venture with other drug makers.

Read the CNBC report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments